To investigate this further using a novel approach, we tested the hypothesis that risk of developing AD would be lower in individuals with genetically predicted, long-term increases in exposure to circulating IGF1 and IGFBP3. The gene discussed is IGFBP3; the disease is Alzheimer disease.